Allogene Therapeutics, Inc.

ALLO

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001737287

SEC filings (opens in a new tab)

In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Allogene Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of ALLO: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Of which not filed for Q3 2025	Q3 2025	Change
Holders	158	2	170	+14
Shares	183.6M	32.4K	162.1M	−21.5M (−11.7%)
Value	$207.9M	$36.6K	$201.0M	−$6.83M (−3.3%)

2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (30)

Institutions that held Allogene Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to ALLO in Q3 2025
Institution	Shares	Value	% of portfolio
D. E. Shaw & Co., Inc.	463,898	$575.2K	0.00%
Bridgeway Capital Management, LLC	250,000	$310.0K	0.01%
Headlands Technologies LLC	139,961	$173.6K	0.01%
HRT Financial LP	132,531	$164.0K	0.00%
Cubist Systematic Strategies, LLC	102,771	$127.4K	0.00%
Atom Investors LP	85,930	$106.6K	0.01%
MetLife Investment Management	57,257	$71.0K	0.00%
Levin Capital Strategies, L.P.	52,500	$65.1K	0.01%
Dynamic Technology Lab Private Ltd	39,677	$50.0K	0.01%
SRS Capital Advisors, Inc.	37,401	$46.4K	0.00%
Mariner, LLC	36,670	$45.5K	0.00%
Scientech Research LLC	26,635	$33.0K	0.01%
Mercer Global Advisors Inc	23,998	$29.8K	0.00%
CIBC Bancorp USA Inc.	16,163	$20.0K	0.00%
Captrust Financial Advisors	15,715	$19.5K	0.00%
DLK Investment Management, LLC	10,000	$12.4K	0.00%
Essential Partners LLC	7,678	$9.52K	0.00%
Rockefeller Capital Management L.P.	7,250	$8.99K	0.00%
Point72 (DIFC) Ltd	6,215	$7.71K	0.00%
Advisory Services Network, LLC	4,069	$5.05K	0.00%
Group One Trading, L.P.	2,268	$2.81K	0.00%
EverSource Wealth Advisors, LLC	1,951	$2.42K	0.00%
Parallel Advisors, LLC	1,485	$1.84K	0.00%
Point72 Europe (London) LLP	1,077	$1.33K	0.00%
Clearstead Advisors, LLC	837	$1.04K	0.00%
Rise Advisors, LLC	827	$1.02K	0.00%
Avion Wealth	883	$1.00K	0.00%
Bell Investment Advisors, Inc	486	$603	0.00%
Sunbelt Securities, Inc.	216	$268	0.00%
True Wealth Design, LLC	216	$268	0.00%

Sold out (16)

Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of ALLO in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Capital World Investors	11,150,000	$12.6M
Darwin Global Management, Ltd.	10,479,791	$12.4M
Foresite Capital Management VI LLC	2,875,357	$3.25M
Gilead Sciences, Inc.	1,156,689	$1.31M
Bourgeon Capital Management LLC	110,000	$124.3K
Brevan Howard Capital Management LP	81,843	$92.5K
State Board of Administration of Florida Retirement System	24,544	$27.7K
Susquehanna Fundamental Investments, LLC	15,077	$17.0K
Rialto Wealth Management, LLC	912	$1.03K
Fortitude Family Office, LLC	747	$844
REAP Financial Group, LLC	200	$226
US Bancorp	184	$208
Federation des caisses Desjardins du Quebec	100	$113
The PNC Financial Services Group, Inc.	85	$96
Raymond James Financial Inc	45	$51
Ball & Co Wealth Management Inc.	500	$0

Not filed for Q3 2025 yet (2)

Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ALLO in Q2 2025 that haven't filed for Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
CIBC World Markets Corp	18,682	$21.1K
EP Wealth Advisors, LLC	13,685	$15.5K